世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

外陰カンジダ症治療薬-世界市場シェア・ランキング、全体売上高・需要予測2025-2031年

外陰カンジダ症治療薬-世界市場シェア・ランキング、全体売上高・需要予測2025-2031年


Drugs for Vulvovaginal Candidiasis- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

外陰カンジダ症治療薬の世界市場は、2024年には8億4,100万米ドル規模と推定され、2031年には9億3,200万米ドルに再調整され、予測期間2025-2031年のCAGRは1.5%と予測されている。 カンジダの細胞壁は、エルゴス... もっと見る

 

 

出版社 出版年月 電子版価格 納期 言語
QYResearch
QYリサーチ
2025年1月10日 US$3,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
5-7営業日 英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

外陰カンジダ症治療薬の世界市場は、2024年には8億4,100万米ドル規模と推定され、2031年には9億3,200万米ドルに再調整され、予測期間2025-2031年のCAGRは1.5%と予測されている。
カンジダの細胞壁は、エルゴステロールの生合成に依存する複雑な糖タンパク質である。抗真菌薬に含まれるアゾール化合物はエルゴステロールの産生を阻害すると考えられており、これにより外用抗真菌薬は80%を超える治癒率を達成できる。米国食品医薬品局(FDA)によりこの適応で承認されている唯一の経口アゾール剤はフルコナゾールであり、これも高い治癒率を達成している。150mgの錠剤を1錠服用後、少なくとも72時間は膣分泌液中に治療濃度が認められる。

カンジダ感染を繰り返す女性の中には、一般にカンジダ症に非常に有効な市販薬(OTC)による治療を選択する人もいる。ブトコナゾール、クロトリマゾール、ミコナゾールおよびチオコナゾールの膣内投与用製剤がOTCで入手可能である。
外陰カンジダ症治療薬の主なメーカーは、バイエル、J&J、ファイザー、ペリゴ、エフィクなどである。世界のトップ3メーカーが市場シェアの約40%を占めている。

アジア太平洋地域が世界最大の市場であり、市場シェアは約45%、次いで北米が約20%である。
本レポートは、外陰カンジダ症治療薬の世界市場について、総販売量、販売収益、価格、主要企業の市場シェアとランキング、外陰カンジダ症治療薬の地域別・国別、タイプ別、用途別の分析を中心に包括的に紹介することを目的としています。

外陰カンジダ症治療薬の市場規模、推計、予測は、2024年を基準年として、2020年から2031年までの期間の履歴データと予測データとともに、販売数量(K単位)と販売収益(百万ドル)で提供されます。定量的および定性的分析により、読者がビジネス/成長戦略を策定し、市場競争状況を評価し、現在の市場における自社のポジションを分析し、外陰カンジダ症治療薬に関する十分な情報に基づいたビジネス上の意思決定を行えるよう支援します。

市場区分
企業別
バイエル
ペリゴ
J & J
ファイザー
ブリストル・マイヤーズ スクイブ
エフィク
テバ
サノフィ
シセン製薬
キンギョークグループ
タイプ別セグメント
クリーム
ペッサリー
その他
用途別セグメント
病院・クリニック
薬局
地域別
北米
米国
カナダ
アジア太平洋
中国
日本
韓国
東南アジア
インド
オーストラリア
その他のアジア太平洋地域
ヨーロッパ
ドイツ
フランス
英国
イタリア
オランダ
北欧諸国
その他のヨーロッパ
ラテンアメリカ
メキシコ
ブラジル
その他のラテンアメリカ
中東・アフリカ
トルコ
サウジアラビア
アラブ首長国連邦
その他のMEA

各章の概要
第1章: レポートの対象範囲、世界の総市場規模(金額、数量、価格)を紹介します。また本章では、市場ダイナミクス、市場の最新動向、市場の促進要因と制限要因、業界メーカーが直面する課題とリスク、業界の関連政策の分析を提供します。
第2章:外陰カンジダ症治療薬メーカーの競争環境、価格、売上高、市場シェア、最新の開発計画、合併・買収情報などを詳細に分析。
第3章:タイプ別に様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる市場セグメントでブルーオーシャン市場を見つけるのを助ける。
第4章:アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展の可能性をカバーし、読者が異なる川下市場でのブルーオーシャン市場を見つけるのに役立ちます。
第5章:外陰カンジダ症治療薬の地域別売上高、収益。各地域の市場規模と発展の可能性を定量的に分析し、世界各国の市場発展、将来の発展展望、市場空間、市場規模を紹介する。
第6章 外陰カンジダ症治療薬の国別売上高、収益。各国・地域のタイプ別、用途別のシグメイトデータを提供。
第7章:主要企業のプロファイルを提供し、製品の売上高、収益、価格、売上総利益率、製品紹介、最近の開発など、市場の主要企業の基本的な状況を詳細に紹介します。
第8章:産業の上流と下流を含む産業チェーンの分析。
第9章:結論


ページTOPに戻る


目次

1 Market Overview
1.1 Drugs for Vulvovaginal Candidiasis Product Introduction
1.2 Global Drugs for Vulvovaginal Candidiasis Market Size Forecast
1.2.1 Global Drugs for Vulvovaginal Candidiasis Sales Value (2020-2031)
1.2.2 Global Drugs for Vulvovaginal Candidiasis Sales Volume (2020-2031)
1.2.3 Global Drugs for Vulvovaginal Candidiasis Sales Price (2020-2031)
1.3 Drugs for Vulvovaginal Candidiasis Market Trends & Drivers
1.3.1 Drugs for Vulvovaginal Candidiasis Industry Trends
1.3.2 Drugs for Vulvovaginal Candidiasis Market Drivers & Opportunity
1.3.3 Drugs for Vulvovaginal Candidiasis Market Challenges
1.3.4 Drugs for Vulvovaginal Candidiasis Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Drugs for Vulvovaginal Candidiasis Players Revenue Ranking (2024)
2.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Company (2020-2025)
2.3 Global Drugs for Vulvovaginal Candidiasis Players Sales Volume Ranking (2024)
2.4 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Company Players (2020-2025)
2.5 Global Drugs for Vulvovaginal Candidiasis Average Price by Company (2020-2025)
2.6 Key Manufacturers Drugs for Vulvovaginal Candidiasis Manufacturing Base and Headquarters
2.7 Key Manufacturers Drugs for Vulvovaginal Candidiasis Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Drugs for Vulvovaginal Candidiasis
2.9 Drugs for Vulvovaginal Candidiasis Market Competitive Analysis
2.9.1 Drugs for Vulvovaginal Candidiasis Market Concentration Rate (2020-2025)
2.9.2 Global 5 and 10 Largest Manufacturers by Drugs for Vulvovaginal Candidiasis Revenue in 2024
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Vulvovaginal Candidiasis as of 2024)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Cream
3.1.2 Pessary
3.1.3 Other
3.2 Global Drugs for Vulvovaginal Candidiasis Sales Value by Type
3.2.1 Global Drugs for Vulvovaginal Candidiasis Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Drugs for Vulvovaginal Candidiasis Sales Value, by Type (2020-2031)
3.2.3 Global Drugs for Vulvovaginal Candidiasis Sales Value, by Type (%) (2020-2031)
3.3 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Type
3.3.1 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Type (2020 VS 2024 VS 2031)
3.3.2 Global Drugs for Vulvovaginal Candidiasis Sales Volume, by Type (2020-2031)
3.3.3 Global Drugs for Vulvovaginal Candidiasis Sales Volume, by Type (%) (2020-2031)
3.4 Global Drugs for Vulvovaginal Candidiasis Average Price by Type (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital & Clinic
4.1.2 Pharmacy
4.2 Global Drugs for Vulvovaginal Candidiasis Sales Value by Application
4.2.1 Global Drugs for Vulvovaginal Candidiasis Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Drugs for Vulvovaginal Candidiasis Sales Value, by Application (2020-2031)
4.2.3 Global Drugs for Vulvovaginal Candidiasis Sales Value, by Application (%) (2020-2031)
4.3 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Application
4.3.1 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Application (2020 VS 2024 VS 2031)
4.3.2 Global Drugs for Vulvovaginal Candidiasis Sales Volume, by Application (2020-2031)
4.3.3 Global Drugs for Vulvovaginal Candidiasis Sales Volume, by Application (%) (2020-2031)
4.4 Global Drugs for Vulvovaginal Candidiasis Average Price by Application (2020-2031)
5 Segmentation by Region
5.1 Global Drugs for Vulvovaginal Candidiasis Sales Value by Region
5.1.1 Global Drugs for Vulvovaginal Candidiasis Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Drugs for Vulvovaginal Candidiasis Sales Value by Region (2020-2025)
5.1.3 Global Drugs for Vulvovaginal Candidiasis Sales Value by Region (2026-2031)
5.1.4 Global Drugs for Vulvovaginal Candidiasis Sales Value by Region (%), (2020-2031)
5.2 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Region
5.2.1 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Region: 2020 VS 2024 VS 2031
5.2.2 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Region (2020-2025)
5.2.3 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Region (2026-2031)
5.2.4 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Region (%), (2020-2031)
5.3 Global Drugs for Vulvovaginal Candidiasis Average Price by Region (2020-2031)
5.4 North America
5.4.1 North America Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
5.4.2 North America Drugs for Vulvovaginal Candidiasis Sales Value by Country (%), 2024 VS 2031
5.5 Europe
5.5.1 Europe Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
5.5.2 Europe Drugs for Vulvovaginal Candidiasis Sales Value by Country (%), 2024 VS 2031
5.6 Asia Pacific
5.6.1 Asia Pacific Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
5.6.2 Asia Pacific Drugs for Vulvovaginal Candidiasis Sales Value by Region (%), 2024 VS 2031
5.7 South America
5.7.1 South America Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
5.7.2 South America Drugs for Vulvovaginal Candidiasis Sales Value by Country (%), 2024 VS 2031
5.8 Middle East & Africa
5.8.1 Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
5.8.2 Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Drugs for Vulvovaginal Candidiasis Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Drugs for Vulvovaginal Candidiasis Sales Value
6.2.1 Key Countries/Regions Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
6.2.2 Key Countries/Regions Drugs for Vulvovaginal Candidiasis Sales Volume, 2020-2031
6.3 United States
6.3.1 United States Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
6.3.2 United States Drugs for Vulvovaginal Candidiasis Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Drugs for Vulvovaginal Candidiasis Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
6.4.2 Europe Drugs for Vulvovaginal Candidiasis Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Drugs for Vulvovaginal Candidiasis Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
6.5.2 China Drugs for Vulvovaginal Candidiasis Sales Value by Type (%), 2024 VS 2031
6.5.3 China Drugs for Vulvovaginal Candidiasis Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
6.6.2 Japan Drugs for Vulvovaginal Candidiasis Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Drugs for Vulvovaginal Candidiasis Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
6.7.2 South Korea Drugs for Vulvovaginal Candidiasis Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Drugs for Vulvovaginal Candidiasis Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
6.8.2 Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
6.9.2 India Drugs for Vulvovaginal Candidiasis Sales Value by Type (%), 2024 VS 2031
6.9.3 India Drugs for Vulvovaginal Candidiasis Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Bayer
7.1.1 Bayer Company Information
7.1.2 Bayer Introduction and Business Overview
7.1.3 Bayer Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Bayer Drugs for Vulvovaginal Candidiasis Product Offerings
7.1.5 Bayer Recent Development
7.2 Perrigo
7.2.1 Perrigo Company Information
7.2.2 Perrigo Introduction and Business Overview
7.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Perrigo Drugs for Vulvovaginal Candidiasis Product Offerings
7.2.5 Perrigo Recent Development
7.3 J & J
7.3.1 J & J Company Information
7.3.2 J & J Introduction and Business Overview
7.3.3 J & J Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 J & J Drugs for Vulvovaginal Candidiasis Product Offerings
7.3.5 J & J Recent Development
7.4 Pfizer
7.4.1 Pfizer Company Information
7.4.2 Pfizer Introduction and Business Overview
7.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Pfizer Drugs for Vulvovaginal Candidiasis Product Offerings
7.4.5 Pfizer Recent Development
7.5 Bristol-Myers Squibb
7.5.1 Bristol-Myers Squibb Company Information
7.5.2 Bristol-Myers Squibb Introduction and Business Overview
7.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product Offerings
7.5.5 Bristol-Myers Squibb Recent Development
7.6 Effik
7.6.1 Effik Company Information
7.6.2 Effik Introduction and Business Overview
7.6.3 Effik Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Effik Drugs for Vulvovaginal Candidiasis Product Offerings
7.6.5 Effik Recent Development
7.7 Teva
7.7.1 Teva Company Information
7.7.2 Teva Introduction and Business Overview
7.7.3 Teva Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Teva Drugs for Vulvovaginal Candidiasis Product Offerings
7.7.5 Teva Recent Development
7.8 Sanofi
7.8.1 Sanofi Company Information
7.8.2 Sanofi Introduction and Business Overview
7.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Sanofi Drugs for Vulvovaginal Candidiasis Product Offerings
7.8.5 Sanofi Recent Development
7.9 Cisen Pharmaceutical
7.9.1 Cisen Pharmaceutical Company Information
7.9.2 Cisen Pharmaceutical Introduction and Business Overview
7.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product Offerings
7.9.5 Cisen Pharmaceutical Recent Development
7.10 Kingyork Group
7.10.1 Kingyork Group Company Information
7.10.2 Kingyork Group Introduction and Business Overview
7.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.10.4 Kingyork Group Drugs for Vulvovaginal Candidiasis Product Offerings
7.10.5 Kingyork Group Recent Development
8 Industry Chain Analysis
8.1 Drugs for Vulvovaginal Candidiasis Industrial Chain
8.2 Drugs for Vulvovaginal Candidiasis Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Drugs for Vulvovaginal Candidiasis Sales Model
8.5.2 Sales Channel
8.5.3 Drugs for Vulvovaginal Candidiasis Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

 

ページTOPに戻る


 

Summary

The global market for Drugs for Vulvovaginal Candidiasis was estimated to be worth US$ 841 million in 2024 and is forecast to a readjusted size of US$ 932 million by 2031 with a CAGR of 1.5% during the forecast period 2025-2031.
The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.

Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.
The main manufacturers of Drugs for Vulvovaginal Candidiasis are Bayer, J & J, Pfizer, Perrigo, Effik, etc. The top three manufacturers in the world occupy about 40% of the market share.

The Asia-Pacific region is the world"s largest market, with a market share of about 45%, followed by North America with nearly 20%
This report aims to provide a comprehensive presentation of the global market for Drugs for Vulvovaginal Candidiasis, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Drugs for Vulvovaginal Candidiasis by region & country, by Type, and by Application.

The Drugs for Vulvovaginal Candidiasis market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Vulvovaginal Candidiasis.

Market Segmentation
By Company
Bayer
Perrigo
J & J
Pfizer
Bristol-Myers Squibb
Effik
Teva
Sanofi
Cisen Pharmaceutical
Kingyork Group
Segment by Type
Cream
Pessary
Other
Segment by Application
Hospital & Clinic
Pharmacy
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Drugs for Vulvovaginal Candidiasis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Drugs for Vulvovaginal Candidiasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Drugs for Vulvovaginal Candidiasis in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.



ページTOPに戻る


Table of Contents

1 Market Overview
1.1 Drugs for Vulvovaginal Candidiasis Product Introduction
1.2 Global Drugs for Vulvovaginal Candidiasis Market Size Forecast
1.2.1 Global Drugs for Vulvovaginal Candidiasis Sales Value (2020-2031)
1.2.2 Global Drugs for Vulvovaginal Candidiasis Sales Volume (2020-2031)
1.2.3 Global Drugs for Vulvovaginal Candidiasis Sales Price (2020-2031)
1.3 Drugs for Vulvovaginal Candidiasis Market Trends & Drivers
1.3.1 Drugs for Vulvovaginal Candidiasis Industry Trends
1.3.2 Drugs for Vulvovaginal Candidiasis Market Drivers & Opportunity
1.3.3 Drugs for Vulvovaginal Candidiasis Market Challenges
1.3.4 Drugs for Vulvovaginal Candidiasis Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Drugs for Vulvovaginal Candidiasis Players Revenue Ranking (2024)
2.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Company (2020-2025)
2.3 Global Drugs for Vulvovaginal Candidiasis Players Sales Volume Ranking (2024)
2.4 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Company Players (2020-2025)
2.5 Global Drugs for Vulvovaginal Candidiasis Average Price by Company (2020-2025)
2.6 Key Manufacturers Drugs for Vulvovaginal Candidiasis Manufacturing Base and Headquarters
2.7 Key Manufacturers Drugs for Vulvovaginal Candidiasis Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Drugs for Vulvovaginal Candidiasis
2.9 Drugs for Vulvovaginal Candidiasis Market Competitive Analysis
2.9.1 Drugs for Vulvovaginal Candidiasis Market Concentration Rate (2020-2025)
2.9.2 Global 5 and 10 Largest Manufacturers by Drugs for Vulvovaginal Candidiasis Revenue in 2024
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Vulvovaginal Candidiasis as of 2024)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Cream
3.1.2 Pessary
3.1.3 Other
3.2 Global Drugs for Vulvovaginal Candidiasis Sales Value by Type
3.2.1 Global Drugs for Vulvovaginal Candidiasis Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Drugs for Vulvovaginal Candidiasis Sales Value, by Type (2020-2031)
3.2.3 Global Drugs for Vulvovaginal Candidiasis Sales Value, by Type (%) (2020-2031)
3.3 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Type
3.3.1 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Type (2020 VS 2024 VS 2031)
3.3.2 Global Drugs for Vulvovaginal Candidiasis Sales Volume, by Type (2020-2031)
3.3.3 Global Drugs for Vulvovaginal Candidiasis Sales Volume, by Type (%) (2020-2031)
3.4 Global Drugs for Vulvovaginal Candidiasis Average Price by Type (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital & Clinic
4.1.2 Pharmacy
4.2 Global Drugs for Vulvovaginal Candidiasis Sales Value by Application
4.2.1 Global Drugs for Vulvovaginal Candidiasis Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Drugs for Vulvovaginal Candidiasis Sales Value, by Application (2020-2031)
4.2.3 Global Drugs for Vulvovaginal Candidiasis Sales Value, by Application (%) (2020-2031)
4.3 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Application
4.3.1 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Application (2020 VS 2024 VS 2031)
4.3.2 Global Drugs for Vulvovaginal Candidiasis Sales Volume, by Application (2020-2031)
4.3.3 Global Drugs for Vulvovaginal Candidiasis Sales Volume, by Application (%) (2020-2031)
4.4 Global Drugs for Vulvovaginal Candidiasis Average Price by Application (2020-2031)
5 Segmentation by Region
5.1 Global Drugs for Vulvovaginal Candidiasis Sales Value by Region
5.1.1 Global Drugs for Vulvovaginal Candidiasis Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Drugs for Vulvovaginal Candidiasis Sales Value by Region (2020-2025)
5.1.3 Global Drugs for Vulvovaginal Candidiasis Sales Value by Region (2026-2031)
5.1.4 Global Drugs for Vulvovaginal Candidiasis Sales Value by Region (%), (2020-2031)
5.2 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Region
5.2.1 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Region: 2020 VS 2024 VS 2031
5.2.2 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Region (2020-2025)
5.2.3 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Region (2026-2031)
5.2.4 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Region (%), (2020-2031)
5.3 Global Drugs for Vulvovaginal Candidiasis Average Price by Region (2020-2031)
5.4 North America
5.4.1 North America Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
5.4.2 North America Drugs for Vulvovaginal Candidiasis Sales Value by Country (%), 2024 VS 2031
5.5 Europe
5.5.1 Europe Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
5.5.2 Europe Drugs for Vulvovaginal Candidiasis Sales Value by Country (%), 2024 VS 2031
5.6 Asia Pacific
5.6.1 Asia Pacific Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
5.6.2 Asia Pacific Drugs for Vulvovaginal Candidiasis Sales Value by Region (%), 2024 VS 2031
5.7 South America
5.7.1 South America Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
5.7.2 South America Drugs for Vulvovaginal Candidiasis Sales Value by Country (%), 2024 VS 2031
5.8 Middle East & Africa
5.8.1 Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
5.8.2 Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Drugs for Vulvovaginal Candidiasis Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Drugs for Vulvovaginal Candidiasis Sales Value
6.2.1 Key Countries/Regions Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
6.2.2 Key Countries/Regions Drugs for Vulvovaginal Candidiasis Sales Volume, 2020-2031
6.3 United States
6.3.1 United States Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
6.3.2 United States Drugs for Vulvovaginal Candidiasis Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Drugs for Vulvovaginal Candidiasis Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
6.4.2 Europe Drugs for Vulvovaginal Candidiasis Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Drugs for Vulvovaginal Candidiasis Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
6.5.2 China Drugs for Vulvovaginal Candidiasis Sales Value by Type (%), 2024 VS 2031
6.5.3 China Drugs for Vulvovaginal Candidiasis Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
6.6.2 Japan Drugs for Vulvovaginal Candidiasis Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Drugs for Vulvovaginal Candidiasis Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
6.7.2 South Korea Drugs for Vulvovaginal Candidiasis Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Drugs for Vulvovaginal Candidiasis Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
6.8.2 Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
6.9.2 India Drugs for Vulvovaginal Candidiasis Sales Value by Type (%), 2024 VS 2031
6.9.3 India Drugs for Vulvovaginal Candidiasis Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Bayer
7.1.1 Bayer Company Information
7.1.2 Bayer Introduction and Business Overview
7.1.3 Bayer Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Bayer Drugs for Vulvovaginal Candidiasis Product Offerings
7.1.5 Bayer Recent Development
7.2 Perrigo
7.2.1 Perrigo Company Information
7.2.2 Perrigo Introduction and Business Overview
7.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Perrigo Drugs for Vulvovaginal Candidiasis Product Offerings
7.2.5 Perrigo Recent Development
7.3 J & J
7.3.1 J & J Company Information
7.3.2 J & J Introduction and Business Overview
7.3.3 J & J Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 J & J Drugs for Vulvovaginal Candidiasis Product Offerings
7.3.5 J & J Recent Development
7.4 Pfizer
7.4.1 Pfizer Company Information
7.4.2 Pfizer Introduction and Business Overview
7.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Pfizer Drugs for Vulvovaginal Candidiasis Product Offerings
7.4.5 Pfizer Recent Development
7.5 Bristol-Myers Squibb
7.5.1 Bristol-Myers Squibb Company Information
7.5.2 Bristol-Myers Squibb Introduction and Business Overview
7.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product Offerings
7.5.5 Bristol-Myers Squibb Recent Development
7.6 Effik
7.6.1 Effik Company Information
7.6.2 Effik Introduction and Business Overview
7.6.3 Effik Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Effik Drugs for Vulvovaginal Candidiasis Product Offerings
7.6.5 Effik Recent Development
7.7 Teva
7.7.1 Teva Company Information
7.7.2 Teva Introduction and Business Overview
7.7.3 Teva Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Teva Drugs for Vulvovaginal Candidiasis Product Offerings
7.7.5 Teva Recent Development
7.8 Sanofi
7.8.1 Sanofi Company Information
7.8.2 Sanofi Introduction and Business Overview
7.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Sanofi Drugs for Vulvovaginal Candidiasis Product Offerings
7.8.5 Sanofi Recent Development
7.9 Cisen Pharmaceutical
7.9.1 Cisen Pharmaceutical Company Information
7.9.2 Cisen Pharmaceutical Introduction and Business Overview
7.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product Offerings
7.9.5 Cisen Pharmaceutical Recent Development
7.10 Kingyork Group
7.10.1 Kingyork Group Company Information
7.10.2 Kingyork Group Introduction and Business Overview
7.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.10.4 Kingyork Group Drugs for Vulvovaginal Candidiasis Product Offerings
7.10.5 Kingyork Group Recent Development
8 Industry Chain Analysis
8.1 Drugs for Vulvovaginal Candidiasis Industrial Chain
8.2 Drugs for Vulvovaginal Candidiasis Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Drugs for Vulvovaginal Candidiasis Sales Model
8.5.2 Sales Channel
8.5.3 Drugs for Vulvovaginal Candidiasis Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります


よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2025/04/03 10:27

148.83 円

162.56 円

196.84 円

ページTOPに戻る